Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up|
Da Silva, LJ
|Abstract:||Background: Patients undergoing dialysis usually have a poor response to conventional hepatitis B vaccination. Aim: To observe the effects of intradermal hepatitis B (HB) vaccination in a 13-month prospective study of adult patients with end-stage renal failure. The patients were with or without previous hepatitis B vaccination, but all had antibody titres < 10 mUI/mL. Methods: Patients were allotted to two groups: previous hepatitis B virus vaccination and no previous hepatitis B virus vaccination or anti-HBs titres < 10 mUI/mL. Patients in both groups received 16 i.d. injections of 0.1 mL of hepatitis B virus vaccine over an eight-week period. Patients had antibody titres assessed before vaccination, 1 month after and every 3 months for a year. Antibody titres >= 10 mUI/mL were considered protective. Results: Seventy patients completed the protocol. Protective titres were elicited in 82% of each group. Age, time under dialysis, diabetes, smoking and body-mass index were not associated with seroconversion. Persistent protective titres > 12 months occurred in 27 (58.7%). Adverse events were trivial. Conclusion: Intradermal hepatitis B virus vaccination is an alternative in end-stage renal failure.|
|Citation:||Alimentary Pharmacology & Therapeutics. Blackwell Publishing, v. 25, n. 7, n. 849, n. 855, 2007.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.